goserelin has been researched along with folligen* in 2 studies
2 other study(ies) available for goserelin and folligen
| Article | Year |
|---|---|
Novel antitumor peptide hormones and their effect on signal transduction.
A series of novel gonadotropin releasing hormone (GnRH) and Somatostatin analogs have been developed in our laboratory and were screened for antiproliferative and signal transduction inhibitory effect. Our GnRH analog Folligen, had significant antitumor activity on DMBA induced mammary carcinomas in rats without blocking ovarian functions. The direct effect of Folligen and Buserelin has been compared on the human breast cancer cell line MDA-MB-231. Folligen was found to be more effective in inhibiting cell proliferation and significant differences were found in the signal transduction pathways activated by these analogs. Our novel Somatostatin analogs were screened for tyrosine kinase inhibition and for antiproliferative effect on human colon tumor cells and for growth hormone (GH) release inhibition in vitro and in vivo. The analog TT-2-50 was significantly more active inhibiting GH release in superfused rat pituitary cells and in vivo than native Somatostatin and it strongly inhibited tyrosine kinase and proliferation while it stimulated protein kinase C activity. Topics: Amino Acid Sequence; Animals; Antineoplastic Agents; Breast Neoplasms; Buserelin; Cell Division; Colonic Neoplasms; Drug Screening Assays, Antitumor; Female; Gonadotropin-Releasing Hormone; Goserelin; Humans; Molecular Sequence Data; Peptides; Protein-Tyrosine Kinases; Rats; Rats, Inbred Strains; Signal Transduction; Somatostatin; Tumor Cells, Cultured | 1992 |
Antitumour activity of folligen, a novel gonadotropin-releasing hormone analogue against DMBA-induced tumours in the rat.
A novel chicken gonadotropin-releasing hormone (GnRH) analogue (Folligen), which has a different mechanism of action than superactive mammalian GnRH analogues, has been developed. In this study we report that in 9,10-dimetyl-1,2-bezanthracene- induced mammary carcinomas in rats, Folligen caused an almost 100% tumour remission during a 3-week daily treatment, without blocking ovarian functions. It decreased oestradiol but not to castration levels, while progesterone was not decreased at all; instead, it was slightly stimulated. The histological picture of the ovaries showed no signs of the inhibition of ovarian functions, but the presence of developing follicles and corpora lutea. In comparison, superactive mammalian GnRH analogues caused similar tumour remission but with hormonal castration and a complete block of ovarian functions. Topics: 9,10-Dimethyl-1,2-benzanthracene; Animals; Antineoplastic Agents; Buserelin; Estradiol; Female; Gonadotropin-Releasing Hormone; Goserelin; Mammary Neoplasms, Experimental; Organ Size; Progesterone; Rats; Rats, Inbred Strains; Time Factors; Uterus | 1992 |